Research programme: nitric oxide-donating therapeutics - NicOx/Merck

Drug Profile

Research programme: nitric oxide-donating therapeutics - NicOx/Merck

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co; NicOx
  • Class
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cardiovascular disorders; Unspecified
  • Discontinued Hypertension

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Undefined in France (PO)
  • 15 Sep 2010 Discontinued - Phase-I for Hypertension in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top